Central nervous system targets of glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter-2 inhibitor

doi:10.3969/j.issn.2096-3351.2022.04.003

您当前的位置：

首页 >

文章列表页 >

Central nervous system targets of glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter-2 inhibitor

更新时间：2023-05-05

- Central nervous system targets of glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter-2 inhibitor
- Journal of Southwest Medical University Vol. 45, Issue 4, Pages: 288-295(2022)
- 作者机构：
  
  1. 上海市浦东医院（复旦大学附属浦东医院）内分泌科（,上海,201399
  2. 上海市血管病变调控与重塑重点实验室,上海,201399
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.2096-3351.2022.04.003
  CLC：
- Published：2022，
  
  Published Online：20 July 2022，
扫描看全文
Central nervous system targets of glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter-2 inhibitor. [J]. Journal of Southwest Medical University 45(4):288-295(2022)
DOI：

Central nervous system targets of glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter-2 inhibitor. [J]. Journal of Southwest Medical University 45(4):288-295(2022) DOI： 10.3969/j.issn.2096-3351.2022.04.003.

摘要

肥胖是2型糖尿病形成最主要的病因，而慢性心衰是2型糖尿病主要的致死原因。在高等哺乳动物中，中枢神经系统通过各种神经内分泌途径调节进食行为和体重，控制着能量代谢相关的各种生理过程。已有很多研究证明肥胖发生、发展与中枢神经内分泌调节障碍有关。另外，很多研究证实，早期2型糖尿病可以通过饮食、运动及药物进行缓解。干预肥胖可以延缓2型糖尿病的发生和并发症的出现。目前内分泌科常用的新药胰高血糖素样肽1受体激动剂（glucagon-like peptide-1 receptor agonist，GLP-1RA）和钠葡萄糖共转运体-2抑制剂（sodium glucose co-transportor-2 inhibitor，SGLT-2i）被发现可以改善肥胖和心血管并发症。GLP-1RA可以减少糖尿病病人26%的心血管并发症；SGLT2i可以减少糖尿病病人30%的慢性心衰发生。但目前，仍然有两个问题困扰着临床医师：1. GLP-1RA是否可以通过血脑屏障（blood-brain-barrier，BBB），并在哪些核团控制饮食和能量平衡。2. SGLT2i是否可以通过BBB并抑制过度激活的交感神经系统，进而起到降低心率、抑制慢性心衰的作用。故本文就这两种药物控制饮食和减少心衰可能的中枢神经系统通路和机制做一总结。

Abstract

Obesity is the primary cause of type 2 diabetes (T2D); Diabetes-related chronic heart failure is also a fatal complication of T2D. The central nervous system regulates feeding behavior and body weight in mammals via several neuroendocrine pathways

as well as many physiological processes related to energy consumption. Numerous studies have linked obesity's onset and progression to endocrine regulation disorders in the central nervous system. As a result

diabetic remission can be achieved in the early onset of T2D using a combination of diet

exercise

and medications. Obesity intervention can delay type 2 diabetes onset and complications. New antidiabetic drugs frequently used in endocrinology

such as glucagon-like peptide-1 receptor agonist (GLP-1RA) and sodium-glucose cotransporter-2 inhibitor (SGLT-2i)

have been observed to improve obesity and cardiovascular issues. GLP-1RA could reduce 26% of the cardiovascular complication; SGLT2i can reduce chronic heart failure by 30% in diabetic patients. There are two questions still puzzle clinicians:1. Whether GLP-1RA transport can across the blood-brain barrier (BBB)

and in which nuclei does it control diet and energy balance？2. Whether SGLT2i can transport across the BBB and inhibit the over-activated sympathetic nervous system

thereby reducing heart rate and inhibiting chronic heart failure？Therefore

this article summarizes the possible central nervous system pathways and mechanisms of these two drugs to control diet and reduce heart failure.

关键词

肥胖2型糖尿病中枢神经系统GLP-1受体激动剂SGLT-2抑制剂

Keywords

ObesityType 2 diabetes mellitusCentral nervous systemGLP-1receptor agonistsSGLT-2 inhibitors

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Mediating effect of disease coping style on the relationship between disease cognition and self-management behavior in patients with type 2 diabetes mellitus

Research advances in the association between perivascular adipose and cardiovascular disease

Clinical features and influencing factors for coronavirus disease 2019-related liver injury

Advances in research on the relationship between obesity and ischemic cerebrovascular disease

Research progress in neuroprotection and neurotoxicity of anesthetics

Related Author

苹

刘晓宁

李倬怡

娄

静

武

红

王瑞华

Related Institution

护理部

开封市中医院：

Drug and Func⁃tional Food Research Center of Southwest Medical University

Department of Academic Affairs of Southwest Medical University

Department of Clinical Medicine，College of Clinical Medicine，Southwest Medical University

⁰